Annual Shareholders Equity
$39.51 M
-$42.37 M-51.74%
31 December 2023
Summary:
Adaptimmune Therapeutics annual stockholders equity is currently $39.51 million, with the most recent change of -$42.37 million (-51.74%) on 31 December 2023. During the last 3 years, it has fallen by -$301.71 million (-88.42%). ADAP annual shareholders equity is now -88.42% below its all-time high of $341.23 million, reached on 31 December 2020.ADAP Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Shareholders Equity
$79.99 M
-$16.29 M-16.92%
30 September 2024
Summary:
Adaptimmune Therapeutics quarterly stockholders equity is currently $79.99 million, with the most recent change of -$16.29 million (-16.92%) on 30 September 2024. Over the past year, it has dropped by -$8.14 million (-9.24%). ADAP quarterly shareholders equity is now -80.37% below its all-time high of $407.58 million, reached on 30 June 2020.ADAP Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ADAP Shareholders Equity Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -51.7% | -9.2% |
| 3 y3 years | -88.4% | -66.8% |
| 5 y5 years | -84.0% | -45.8% |
ADAP Shareholders Equity High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -88.4% | at low | -66.8% | +228.2% |
| 5 y | 5 years | -88.4% | at low | -80.4% | +228.2% |
| alltime | all time | -88.4% | +1933.0% | -80.4% | +3219.1% |
Adaptimmune Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $79.99 M(-16.9%) |
| June 2024 | - | $96.27 M(+295.0%) |
| Mar 2024 | - | $24.38 M(-38.3%) |
| Dec 2023 | $39.51 M(-51.7%) | $39.51 M(-55.2%) |
| Sept 2023 | - | $88.13 M(-30.4%) |
| June 2023 | - | $126.65 M(+51.0%) |
| Mar 2023 | - | $83.88 M(+2.4%) |
| Dec 2022 | $81.88 M(-60.2%) | $81.88 M(-27.8%) |
| Sept 2022 | - | $113.34 M(-20.1%) |
| June 2022 | - | $141.92 M(-13.0%) |
| Mar 2022 | - | $163.15 M(-20.8%) |
| Dec 2021 | $205.96 M(-39.6%) | $205.96 M(-14.5%) |
| Sept 2021 | - | $240.98 M(-13.3%) |
| June 2021 | - | $277.94 M(-10.1%) |
| Mar 2021 | - | $309.16 M(-9.4%) |
| Dec 2020 | $341.23 M(+176.0%) | $341.23 M(-9.3%) |
| Sept 2020 | - | $376.21 M(-7.7%) |
| June 2020 | - | $407.58 M(+119.1%) |
| Mar 2020 | - | $186.04 M(+50.5%) |
| Dec 2019 | $123.64 M | $123.64 M(-16.3%) |
| Sept 2019 | - | $147.68 M(-21.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2019 | - | $186.99 M(-14.9%) |
| Mar 2019 | - | $219.66 M(-11.0%) |
| Dec 2018 | $246.88 M(+21.6%) | $246.88 M(-10.6%) |
| Sept 2018 | - | $276.15 M(+67.3%) |
| June 2018 | - | $165.10 M(-13.7%) |
| Mar 2018 | - | $191.26 M(-5.8%) |
| Dec 2017 | $202.98 M(+22.2%) | $202.98 M(-11.4%) |
| Sept 2017 | - | $228.99 M(-0.2%) |
| June 2017 | - | $229.50 M(+10.2%) |
| Mar 2017 | - | $208.33 M(+25.4%) |
| Dec 2016 | $166.14 M(-29.3%) | $166.14 M(-7.7%) |
| Sept 2016 | - | $180.00 M(-8.6%) |
| June 2016 | - | $196.99 M(-10.0%) |
| Mar 2016 | - | $218.95 M(-12.7%) |
| Dec 2015 | $234.99 M(-9.3%) | - |
| Sept 2015 | - | $250.68 M(+172.9%) |
| June 2015 | $259.00 M(>+9900.0%) | - |
| Dec 2014 | - | $91.86 M(+3711.8%) |
| June 2014 | $2.41 M(-211.8%) | $2.41 M |
| June 2013 | -$2.16 M(+1614.9%) | - |
| June 2012 | -$125.70 K | - |
FAQ
- What is Adaptimmune Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual shareholders equity year-on-year change?
- What is Adaptimmune Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly shareholders equity year-on-year change?
What is Adaptimmune Therapeutics annual stockholders equity?
The current annual shareholders equity of ADAP is $39.51 M
What is the all time high annual shareholders equity for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual stockholders equity is $341.23 M
What is Adaptimmune Therapeutics annual shareholders equity year-on-year change?
Over the past year, ADAP annual stockholders equity has changed by -$42.37 M (-51.74%)
What is Adaptimmune Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of ADAP is $79.99 M
What is the all time high quarterly shareholders equity for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly stockholders equity is $407.58 M
What is Adaptimmune Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, ADAP quarterly stockholders equity has changed by -$8.14 M (-9.24%)